1. 1391PImmune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy. (23rd October 2018) Authors: Meliàn Sosa, M; Puchades, C; Mendez, J A; Torres, A; Rodrigo, C; Gimeno, G; Rama, E; Martínez-Castillo, A; Caballero Daroqui, J; Gomez Codina, J; Juan-Vidal, O; Lorente, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1486PRisk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification. (23rd October 2018) Authors: Salvador Coloma, C; Lorente, D; Escoin, C; Mendez, J A; Juan-Vidal, O Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 809PStatin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial. (23rd October 2018) Authors: Lorente, D; De Velasco Oria, G A; Carles, J; Gillessen, S; Fizazi, K; Joshua, A; Eisenberger, M; Sartor, O; de Bono, J S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 860TiPPhase II trial evaluating olaparib maintenance in patients with MCRPC after docetaxel treatment reaching partial or stable response. (23rd October 2018) Authors: Juan Fita, M J; Heras Lopez, L; Mellado, B; Mendez Vidal, M J; Anido, U; Lorente, D; Sepulveda, J M; Alvarez, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration‐Resistant Prostate Cancer1. (24th April 2015) Authors: Wilbaux, M; Tod, M; De Bono, J; Lorente, D; Mateo, J; Freyer, G; You, B; Hénin, E Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 4:Number 5(2015:May) Page Start: 277 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. (7th May 2018) Authors: Lorente, D; Olmos, D; Mateo, J; Dolling, D; Bianchini, D; Seed, G; Flohr, P; Crespo, M; Figueiredo, I; Miranda, S; Scher, H I; Terstappen, L W M M; de Bono, J S Journal: Annals of oncology Issue: Volume 29:Number 7(2018) Page Start: 1554 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗